Results 21 to 30 of about 11,407 (210)

Acetylcysteine increases sensitivity of ceftazidime-avibactam–resistant enterobacterales with different enzymatic resistance to ceftazidime-avibactam in vitro and in vivo

BMC Microbiology, 2023
Abstract Background Ceftazidime-avibactam (CZA) improves treatment outcomes for infections caused by carbapenem-resistant organisms, but has led to serious bacterial resistance. Acetylcysteine (NAC) is an approved medication that protects the respiratory tract through antioxidant and anti-inflammatory effects.
Zeyu Huang, Yijia Han, Xiaotuan Zhang, Yao Sun, Yuzhan Lin, Luozhu Feng, Tieli Zhou, Zhongyong Wang   +7 more
openaire   +3 more sources

A Ceftazidime-Avibactam-Resistant and Carbapenem-Susceptible Klebsiella pneumoniae Strain Harboring bla_KPC-14 Isolated in New York City

mSphere, 2020
Ceftazidime-avibactam is a potent antibiotic combination against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae. Here, we describe a unique ceftazidime-avibactam-resistant and carbapenem-susceptible K.
Siqiang Niu, Kalyan D. Chavda, Jie Wei, Chunhong Zou, Steven H. Marshall, Puneet Dhawan, Deqiang Wang, Robert A. Bonomo, Barry N. Kreiswirth, Liang Chen   +9 more
doaj   +3 more sources

Colistin Does Not Potentiate Ceftazidime-Avibactam Killing of Carbapenem-Resistant Enterobacteriaceae In Vitro or Suppress Emergence of Ceftazidime-Avibactam Resistance [PDF]

Antimicrobial Agents and Chemotherapy, 2018
We tested ceftazidime-avibactam and colistin against 24 carbapenem-resistant Enterobacteriaceae (CRE) isolates by time-kill studies. Ceftazidime-avibactam at 0.25×, 1×, and 4× the MIC was bactericidal against 8%, 21%, and 88% of the isolates, respectively.
Ryan K, Shields, M Hong, Nguyen, Binghua, Hao, Ellen G, Kline, Cornelius J, Clancy   +4 more
openaire   +2 more sources

Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia [PDF]

, 2020
BACKGROUND: Cefiderocol is a novel siderophore cephalosporin, developed for activity against MDR Gram-negative bacilli (MDR-GNB). OBJECTIVES: To assess the in vitro antibacterial activity of cefiderocol against a collection of MDR-GNB clinical ...
Conejo, Mª del Carmen, Delgado Valverde, María Mercedes, Fernández Cuenca, Felipe Manuel, Pascual Hernández, Álvaro, Serrano, Lara   +4 more
core   +1 more source

Molecular analysis of clinical isolates of ceftazidime-avibactam-resistant Klebsiella pneumoniae [PDF]

Clinical Microbiology and Infection, 2021
To analyse the strains collected during a 1-year survey of ceftazidime-avibactam-resistant KPC-producing Klebsiella pneumoniae, in order to investigate the molecular mechanisms potentially responsible for their resistant phenotype.Clinical KPC-producing K. pneumoniae isolates were collected from 31 patients in six different hospitals in Rome. For eight
Carolina, Venditti, Ornella, Butera, Marcello, Meledandri, Maria Pia, Balice, Giulio Cesare, Cocciolillo, Carla, Fontana, Silvia, D'Arezzo, Chiara, De Giuli, Mario, Antonini, Alessandro, Capone, Francesco, Messina, Carla, Nisii, Antonino, Di Caro   +12 more
openaire   +2 more sources

In Vitro and In Vivo Evaluations of β-Lactam/β-Lactamase Mono- and Combined Therapies against Carbapenem-Nonsusceptible Enterobacteriaceae in Taiwan

Microorganisms, 2020
Increasing carbapenem resistance rates worldwide underscored the urgent need of novel antimicrobials. Ceftazidime–avibactam and aztreonam–avibactam combinations are developed to combat carbapenem resistance, but biological and geographic variations must ...
Tsung-Ying Yang, Ya-Ju Hsieh, Li-Ting Kao, Guan-Hong Liu, Shao-Hsuan Lian, Liang-Chun Wang, I-Ling Lin, Yu-Tzu Lin, Sheng-Fan Wang, Sung-Pin Tseng, Po-Liang Lu   +10 more
doaj   +1 more source

Ceftolozane–tazobactam- and ceftazidime–avibactam-resistant Pseudomonas aeruginosa mastoiditis

Access Microbiology, 2020
Pseudomonas aeruginosa is an important bacterial cause of a variety of infections and is associated with high morbidity and mortality. Infections caused by this bacterium are becoming more difficult to treat due to increasing resistance to many of the available antibiotics. Ceftolozane–tazobactam and ceftazidime–avibactam are two new
Jeremy Jacobs, Alexander Maris, Charles Stratton   +2 more
openaire   +2 more sources

Clinical Efficacy of Ceftazidime-Avibactam in the Treatment of Infections Caused by Carbapenem–Resistant Gram-Negative Bacteria

Антибиотики и Химиотерапия, 2021
The wide spread of carbapenemases among gram-negative bacteria of the Enterobacterales order in hospitals around the world, including Russia, creates great difficulties in the effective use of antibiotics for these infections in the ICU.
S. V. Yakovlev
doaj   +1 more source

Ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae accompanied hypermucoviscosity acquisition. [PDF]

BMC Microbiol
Antimicrobial resistance and bacterial hypermucoviscosity, associated with escalating production of capsules, constitute major challenges for the clinical management of Klebsiella pneumoniae (K. pneumoniae) infections. This study investigates the association and underlying mechanism between ceftazidime-avibactam (CAZ-AVI) resistance and bacterial ...
Guo Y, Wang J, Yao L, Wang Y, Zhang Y, Zhuo C, Yang X, Li F, Li J, Liu B, He N, Chen J, Xiao S, Lin Z, Zhuo C.   +14 more
europepmc   +4 more sources

Effect of β-lactamase inhibitors on in vitro activity of β-lactam antibiotics against Burkholderia cepacia complex species [PDF]

, 2016
Background: Bacteria belonging to the Burkholderia cepacia complex (Bcc) are an important cause of chronic respiratory tract infections in cystic fibrosis patients. Intrinsic resistance to a wide range of antimicrobial agents, including a variety of beta-
Coenye, Tom, Everaert, Annelien
core   +2 more sources